Oral and Inhaled P38 MAPK Inhibitors: Effects on Inhaled LPS Challenge in Healthy Subjects

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2015 Aug 13

PMID 26265232

Citations 11

Authors

Dave Singh

Leonard Siew

Jared Christensen

Jonathan Plumb

Graham W Clarke

Steve Greenaway

Christelle Perros-Huguet

Nick Clarke

Iain Kilty

Lisa Tan

Affiliations

Soon will be listed here.

Abstract

Background: Inhaled LPS causes neutrophilic airway inflammation in healthy subjects. We compared the effects of p38 MAPK inhibitors and fluticasone propionate on the LPS response.

Methods: Three randomised, double-blind, placebo-controlled, single dose crossover studies were performed. Active treatments were the oral p38 MAPK inhibitor PH-797804 30 mg (study 1), PH-797804 30 mg and the inhaled p38 MAPK inhibitor PF-03715455 20 mg (study 2) and inhaled fluticasone propionate 500 μg (study 3). The primary endpoint was sputum neutrophil percentage.

Results: Sputum neutrophil percentage post-LPS challenge was significantly inhibited (15.1 and 15.3% reduction) by PH-797804 compared to placebo in studies 1 and 2 (p = 0.0096 and 0.0001, respectively), and by PF-03715455 (8.0% reduction, p = 0.031); fluticasone propionate had no effect. PH-797804 significantly inhibited the increase in inflammatory mediators (IL-6, MCP-1, MIP1β and CC16) in sputum supernatant, while PF-03715455 had no effect. PH-797804 and PF-03715455 both inhibited IL-6, MCP-1, MIP1β, CC16 and CRP levels in plasma, with PH-797804 having greater effects. Fluticasone propionate had no effect on sputum supernatant or plasma biomarkers.

Conclusions: PH-797804 had the greatest impact on neutrophilic airway inflammation. Oral administration of p38 MAPK inhibitors may optimise pulmonary anti-inflammatory effects.

Citing Articles

The impact of tangeretin combined with whey protein on exercise-induced bronchoconstriction in professional athletes: a placebo-controlled trial.

Cao Z, Zhao C, Mo S, Gao B, Liu M J Int Soc Sports Nutr. 2024; 21(1):2414870.

PMID: 39422600 PMC: 11492410. DOI: 10.1080/15502783.2024.2414870.

CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powder.

Martucci C, Allen A, Moretto N, Bagnacani V, Fioni A, Patacchini R Front Pharmacol. 2024; 15:1343941.

PMID: 38549671 PMC: 10973839. DOI: 10.3389/fphar.2024.1343941.

Transcriptomic characterization of the human segmental endotoxin challenge model.

Gress C, Litzenburger T, Schmid R, Xiao K, Heissig F, Muller M Sci Rep. 2024; 14(1):1721.

PMID: 38242945 PMC: 10798985. DOI: 10.1038/s41598-024-51547-0.

The future of inhalation therapy in chronic obstructive pulmonary disease.

Cazzola M, Ora J, Calzetta L, Rogliani P, Matera M Curr Res Pharmacol Drug Discov. 2022; 3:100092.

PMID: 35243334 PMC: 8866667. DOI: 10.1016/j.crphar.2022.100092.

The Impact of Sex Chromosomes in the Sexual Dimorphism of Pulmonary Arterial Hypertension.

Predescu D, Mokhlesi B, Predescu S Am J Pathol. 2022; 192(4):582-594.

PMID: 35114193 PMC: 8978209. DOI: 10.1016/j.ajpath.2022.01.005.

References

Parameswaran K, Inman M, Watson R, Morris M, Efthimiadis A, Ventresca P . Protective effects of fluticasone on allergen-induced airway responses and sputum inflammatory markers. Can Respir J. 2000; 7(4):313-9. DOI: 10.1155/2000/254213. View

Ketchell R, Jensen M, Lumley P, Wright A, Allenby M, OConnor B . Rapid effect of inhaled fluticasone propionate on airway responsiveness to adenosine 5'-monophosphate in mild asthma. J Allergy Clin Immunol. 2002; 110(4):603-6. DOI: 10.1067/mai.2002.128486. View

Renda T, Baraldo S, Pelaia G, Bazzan E, Turato G, Papi A . Increased activation of p38 MAPK in COPD. Eur Respir J. 2007; 31(1):62-9. DOI: 10.1183/09031936.00036707. View

Calverley P, Anderson J, Celli B, Ferguson G, Jenkins C, Jones P . Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007; 356(8):775-89. DOI: 10.1056/NEJMoa063070. View

Hogg J, Chu F, Utokaparch S, Woods R, Elliott W, Buzatu L . The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004; 350(26):2645-53. DOI: 10.1056/NEJMoa032158. View

Singh D, Smyth L, Borrill Z, Sweeney L, Tal-Singer R . A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients. J Clin Pharmacol. 2009; 50(1):94-100. DOI: 10.1177/0091270009347873. View

Ovrevik J, Lag M, Holme J, Schwarze P, Refsnes M . Cytokine and chemokine expression patterns in lung epithelial cells exposed to components characteristic of particulate air pollution. Toxicology. 2009; 259(1-2):46-53. DOI: 10.1016/j.tox.2009.01.028. View

Saklatvala J . The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol. 2004; 4(4):372-7. DOI: 10.1016/j.coph.2004.03.009. View

Genovese M, Cohen S, Wofsy D, Weinblatt M, Firestein G, Brahn E . A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J Rheumatol. 2011; 38(5):846-54. DOI: 10.3899/jrheum.100602. View

10.

Chung K . p38 mitogen-activated protein kinase pathways in asthma and COPD. Chest. 2011; 139(6):1470-1479. DOI: 10.1378/chest.10-1914. View

11.

Armstrong J, Harbron C, Lea S, Booth G, Cadden P, Wreggett K . Synergistic effects of p38 mitogen-activated protein kinase inhibition with a corticosteroid in alveolar macrophages from patients with chronic obstructive pulmonary disease. J Pharmacol Exp Ther. 2011; 338(3):732-40. DOI: 10.1124/jpet.111.180737. View

12.

Lomas D, Lipson D, Miller B, Willits L, Keene O, Barnacle H . An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. J Clin Pharmacol. 2011; 52(3):416-24. DOI: 10.1177/0091270010397050. View

13.

Cazzola M, Page C, Calzetta L, Matera M . Emerging anti-inflammatory strategies for COPD. Eur Respir J. 2012; 40(3):724-41. DOI: 10.1183/09031936.00213711. View

14.

Moretto N, Bertolini S, Iadicicco C, Marchini G, Kaur M, Volpi G . Cigarette smoke and its component acrolein augment IL-8/CXCL8 mRNA stability via p38 MAPK/MK2 signaling in human pulmonary cells. Am J Physiol Lung Cell Mol Physiol. 2012; 303(10):L929-38. DOI: 10.1152/ajplung.00046.2012. View

15.

Gaffey K, Reynolds S, Plumb J, Kaur M, Singh D . Increased phosphorylated p38 mitogen-activated protein kinase in COPD lungs. Eur Respir J. 2012; 42(1):28-41. DOI: 10.1183/09031936.00170711. View

16.

MacNee W, Allan R, Jones I, De Salvo M, Tan L . Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial. Thorax. 2013; 68(8):738-45. DOI: 10.1136/thoraxjnl-2012-202744. View

17.

Leaker B, Barnes P, OConnor B . Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist. Respir Res. 2013; 14:137. PMC: 3867427. DOI: 10.1186/1465-9921-14-137. View

18.

Watz H, Barnacle H, Hartley B, Chan R . Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014; 2(1):63-72. DOI: 10.1016/S2213-2600(13)70200-5. View

19.

Gupta V, Banyard A, Mullan A, Sriskantharajah S, Southworth T, Singh D . Characterization of the inflammatory response to inhaled lipopolysaccharide in mild to moderate chronic obstructive pulmonary disease. Br J Clin Pharmacol. 2014; 79(5):767-76. PMC: 4415713. DOI: 10.1111/bcp.12546. View

20.

Pizzichini E, Pizzichini M, Efthimiadis A, Evans S, Morris M, Squillace D . Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med. 1996; 154(2 Pt 1):308-17. DOI: 10.1164/ajrccm.154.2.8756799. View